Abstract: The invention concerns a process for preparing a pharmaceutical formulation comprising an insulin derivative, wherein the process comprises dissolving an insulin derivative in water, adjusting the pH of the solution to a pH above 7.2, adding a zinc solution while stirring continuously and adjusting the pH to the target pH of the formulation.

Abstract: The invention concerns a process for preparing a pharmaceutical formulation comprising an insulin derivative, wherein the process comprises dissolving an insulin derivative in water, adjusting the pH of the solution to a pH above 7.2, adding a zinc solution while stirring continuously and adjusting the pH to the target pH of the formulation.

Abstract: The invention concerns a process for preparing a pharmaceutical formulation comprising an insulin derivative, wherein the process comprises dissolving an insulin derivative in water, adjusting the pH of the solution to a pH above 7.2, adding a zinc solution while stirring continuously and adjusting the pH to the target pH of the formulation.

Abstract: The invention concerns a process for preparing a pharmaceutical formulation comprising an insulin derivative, wherein the process comprises dissolving an insulin derivative in water, adjusting the pH of the solution to a pH above 7.2, adding a zinc solution while stirring continuously and adjusting the pH to the target pH of the formulation.

Abstract: A method and an apparatus for sterilizing packaging material for use in packaging for protein containing products, such as food products or medical drugs. The packaging material is sterilized by irradiating it using a beam of ionizing radiation, such as an electron beam or a beam of gamma rays. Afterwards, the packaging material is processed in such a manner that protein reactive substances or compounds formed in the packaging material during the irradiation step are at least partly removed or rendered inreactive with respect to proteins. The processing step may advantageously be performed by heating the packaging material. Preferably, the processing step involves accelerating diffusion from the packaging material of protein reactive substances or compounds. Since the protein reactive substances or compounds are removed or rendered inreactive with respect to proteins, degradation of the product which is later stored in the packaging material is considerably reduced.

Abstract: The present invention relates to a medication delivery device for delivering a set dose of medicament, the medication delivery device comprising pump means having first and second pump chambers. The first pump chamber is adapted to transfer medicament from a first collapsible reservoir to an outlet arrangement, said outlet arrangement being in fluidic communication with an associated hypodermic needle. The second pump chamber is adapted to transfer substance from a second reservoir to the outlet arrangement, wherein the first pump chamber is adapted to deliver the set dose of medicament during one or more pump strokes, the stroke volume(s) of said one or more pump strokes being variable.

Abstract: A method and an apparatus for sterilizing packaging material for use in packaging for protein containing products, such as food products or medical drugs. The packaging material is sterilized by irradiating it using a beam of ionizing radiation, such as an electron beam or a beam of gamma rays. Afterwards, the packaging material is processed in such a manner that protein reactive substances or compounds formed in the packaging material during the irradiation step are at least partly removed or rendered inreactive with respect to proteins. The processing step may advantageously be performed by heating the packaging material. Preferably, the processing step involves accelerating diffusion from the packaging material of protein reactive substances or compounds. Since the protein reactive substances or compounds are removed or rendered inreactive with respect to proteins, degradation of the product which is later stored in the packaging material is considerably reduced.

Abstract: The invention provides a reservoir unit with a reservoir arranged within a housing. The reservoir defines an interior adapted to contain a translucent fluid drug, and comprises a first transparent area. A second area is associated with the reservoir and arranged substantially opposite the first area, the second area comprising a visually non-uniform portion. The housing comprises an inspection portion allowing a user to inspect a portion of the reservoir through the first area with the second area serving as a background, the second area thereby serving as an aid for evaluating a condition of a drug contained in the reservoir, e.g. fibrillated insulin.

Abstract: A substance including the chemical structures of bicyclo[3.2.1]octan or the chemical structures of kaurene for the use in a dietary supplementation or as a constituent in a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome. The unique chemical structures of bicyclo[3.2.1]octan alone or in a kaurene structure provides the substances, such as e.g. steviol, isosteviol and stevioside with the capability of enhancing or potentiating the secretion of insulin in a plasma glucose dependent manner. The substances including these unique chemical structures also have the capability of reducing the glucagon concentration in the blood and/or lowering the blood pressure thereby providing a self-regulatory treatment system for non-insulin dependent diabetes mellitus and/or hypertension.

Abstract: The conduit device (1) is intended for conducting a fluid from a fluid source to a recipient. A tubular portion (2) of the conduit device has an inner side that is intended for contact with the fluid. Means are provided for adapting the surface tension of the inner side of at least the tubular portion and/or the fluid.

Abstract: A substance including the chemical structures of bicyclo [3.2.1]octan or the chemical structures of kaurene for the use in a dietary supplementation or as a constituent in a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome. The unique chemical structures of bicyclo [3.2.1]octan alone or in a kaurene structure provides the substances, such as e.g. steviol, isosteviol and stevioside with the capability of enhancing or potentiating the secretion of insulin in a plasma glucose dependent manner. The substances including these unique chemical structures also have the capability of reducing the glucagon concentration in the blood and/or lowering the blood pressure thereby providing a self-regulatory treatment system for non-insulin dependent diabetes mellitus and/or hypertension.

Abstract: A substance including the chemical structures of bicyclo [3.2.1]octan or the chemical structures of kaurene for the use in a dietary supplementation or as a constituent in a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome. The unique chemical structures of bicyclo [3.2.1]octan alone or in a kaurene structure provides the substances, such as e.g. steviol, isosteviol and stevioside with the capability of enhancing or potentiating the secretion of insulin in a plasma glucose dependent manner. The substances including these unique chemical structures also have the capability of reducing the glucagon concentration in the blood and/or lowering the blood pressure thereby providing a self-regulatory treatment system for non-insulin dependent diabetes mellitus and/or hypertension.